Division of Pharmaceutical Technology, Faculty of Pharmacy, P.O. Box 56 (Viikinkaari 5 E), FI-00014 University of Helsinki, Finland.
Curr Drug Metab. 2012 Oct;13(8):1068-86. doi: 10.2174/138920012802850047.
Several of the newly developed drug molecules show potent biological activity, but exhibit poor pharmacokinetic properties that may hinder their effective delivery to the intended site of action. In order to improve their pharmacological effect, these molecules can be associated with drug carriers in order to overcome these inherent difficulties. An ideal drug delivery agent requires therefore biocompatibility, improved solubility of a loaded drug or peptide, releasing of the payload at the absorption site and, at the same time, leaving undisturbed cell structure and function, and maintaining the physiological milieu. By taking advantage of the valuable properties of nanoscale delivery systems, such as increased surface area, improved solubility of hydrophobic drugs, possibility to encapsulate and protect drugs from degradation and reduced immunogenic potential and toxicological effect, new therapeutic options can be brought forth and improve the clinical arsenal for numerous diseases. The use of nanodelivery systems can even promote the re-investigation of pharmacokinetically less favourable, but biologically more active compounds. Although very promising, these systems may also encompass inherent toxicological issues, mainly due to their size and shape, physical interaction with cellular membranes and organelles, immunological reactions, long- or short-term tissue accumulation, and degradation products. Pharmaceutical nanodelivery systems, such as liposomes, polymeric nanoparticles, dendrimers and mesoporous silica and silicon based nanoparticles have shown great potential in preclinical applications and several of these nanosystems are even undergoing clinical trials. They have been found to combine drug delivery properties with an acceptable toxicological profile, which has made them prime candidates for several drug delivery approaches. This review aims to provide and correlate the toxicological studies with the drug delivery properties of the above mentioned nanodelivery systems in particular concerning uptake and accumulation as well as the critical aspects in each system regarding their optimal performance, while pointing out to the most relevant references.
几种新开发的药物分子表现出很强的生物活性,但表现出较差的药代动力学特性,这可能会阻碍它们有效递送到预期的作用部位。为了提高它们的药理作用,可以将这些分子与药物载体结合,以克服这些固有困难。因此,理想的药物递送剂需要具有生物相容性、提高载药或肽的溶解度、在吸收部位释放有效载荷,同时不干扰细胞结构和功能,并保持生理环境。利用纳米递药系统的宝贵特性,如增加表面积、提高疏水性药物的溶解度、封装和保护药物免受降解的可能性,以及降低免疫原性和毒理学效应,可以带来新的治疗选择,并为许多疾病增加临床武器库。纳米递药系统的应用甚至可以促进对药代动力学较差但生物学活性更高的化合物的重新研究。尽管这些系统非常有前途,但它们也可能包含固有的毒理学问题,主要是由于它们的大小和形状、与细胞膜和细胞器的物理相互作用、免疫反应、长期或短期的组织积累以及降解产物。脂质体、聚合物纳米颗粒、树枝状大分子和介孔硅及硅基纳米颗粒等药物纳米递药系统在临床前应用中显示出巨大的潜力,其中一些纳米系统甚至正在进行临床试验。它们被发现将药物递送特性与可接受的毒理学特征结合在一起,这使它们成为几种药物递送方法的首选候选物。本综述旨在提供和关联上述纳米递药系统的毒理学研究与药物递送特性,特别是关于摄取和积累,以及每个系统在最佳性能方面的关键方面,同时指出最相关的参考文献。
Curr Drug Metab. 2012-10
Future Med Chem. 2009-9
Expert Opin Drug Metab Toxicol. 2015-3
J Colloid Interface Sci. 2017-11-22
Adv Cancer Res. 2018-5-18
J Pharm Sci. 2015-3
Int J Pharm. 2012-9-8
Mater Chem Front. 2021-9-21
Pharmaceutics. 2020-3-2
Toxicol Res (Camb). 2015-10-5
J Control Release. 2013-3-18